, Volume 11, Issue 12, pp 736-743

Racial differences in the medical treatment of elderly medicare patients with acute myocardial infarction

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

OBJECTIVE: To compare the use of medications in African-American and Caucasian elderly Medicare patients hospitalized with acute myocardial infarction (AMI) in Alabama.

DESIGN: Retrospective medical record review.

SETTING: All acute care hospitals in Alabama.

PATIENTS: All Medicare patients with a principal discharge diagnosis of AMI from June 1992 through February 1993. We excluded those patients less than 65 years of age and those of ethnicity other than African-American or Caucasian (N=4,052).

MEASUREMENTS: We first performed a crude analysis using all cases to compare by race the use of thrombolysis, β-adrenergic blockade, and aspirin in the setting of AMI. In addition, we developed a multivariable model with receipt of therapy as the outcome and demographics, severity of illness, comorbidity, and algorithm-determined candidacy for therapy as covariates. The algorithms, developed as part of the Cooperative Cardiovascular Project, were designed to identify an “ideal” pool of candidates for each therapy.

MAIN RESULTS: For all cases, 9.2% (95% confidence interval [CI] 6.8, 12.1) of African Americans received thrombolysis compared with 17.3% (95% CI 16.0, 18.6) of Caucasians. Approximately 16.4% of patients received β-adienergic blockade, and 45.1% received aspirin, both with no racial difference. By multivariate analysis, the adjusted odds ratio for African Americans receiving thrombolysis was 0.55 (95% CI 0.41, 0.76). The corresponding odds ratio was 1.25 (95% CI 0.99, 1.59) for p-adrenergic blockade and 1.13 (95% CI 0.96, 1.37) for aspirin. African Americans presented later after the onset of chest pain, but the refusal rate of thrombolytic therapy did not differ.

CONCLUSIONS: According to this analysis, Alabama physicians used β-adrenergic blockade and aspirin equivalently in African Americans and Caucasians. African Americans received thrombolysis less often according to the crude analysis. The multivariable analysis suggests less use of thrombolytics, even after adjusting for several covariates including indication by clinical algorithm. However, the small number of African-American patients deemed ideal candidates for thrombolysis attenuates the precision of this finding.

Received from the Division of General Internal Medicine and the Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, and Alabama Quality Assurance Foundation (AQAF).
This paper expresses solely the opinion of the authors, and not that of the Health Care Financing Administration.
This research was supported in part by Agency for Health Care Policy and Research Grant #1 U18 HS-9446.